Literature DB >> 21042835

Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma.

Hikmet Akkız1, Süleyman Bayram, Aynur Bekar, Ersin Akgöllü, Yakup Ülger.   

Abstract

Cyclooxygenase-2 (COX-2) influences carcinogenesis through immune response suppression, apoptosis inhibition, regulation of angiogenesis and tumor cell invasion, and metastasis. It is now well established that COX-2 is overexpressed in many premalignant, malignant, and metastatic cancers, including hepatocellular carcinoma (HCC). DNA sequence variations in the COX-2 gene may lead to altered COX-2 production and/or activity, and so they cause inter-individual differences in the susceptibility to HCC. Functional coding region polymorphisms -1195A>G (rs689466), -765G>C (rs20417), and +8473T>C (rs5275) in the COX-2 gene have recently been shown to be associated with several human cancers but their association with HCC has yet to be investigated. We used hospital-based case-control study to assess the hypothesis that the functional COX-2 variation may affect individual susceptibility to the HCC. COX-2 polymorphisms were investigated in 129 confirmed subjects with HCC and 129 cancer-free control subjects matched on age, gender, smoking, and alcohol consumption using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. The distribution of the COX-2 -1195A>G and +8473T>C genotypes were not significantly different between HCC cases and control. However, proportion of the COX-2 -765CC genotype which leads to a 30% reduction of the COX-2 promoter activity was significantly lower in patients with HCC (3.1%) when compared to control subjects (11.6%) (P < 0.05). Logistic regression analyses revealed that the COX-2 -765G>C variant genotype (-765CC) was associated with a significantly decreased risk of HCC compared with the -765GG wild-type homozygotes [P < 0.05, odds ratio (OR) = 0.25, 95% confidence interval (CI) = 0.08-0.79]. Our results suggest for the first time that the -765CC genotype of COX-2 -765G>C polymorphism, causing lower COX-2 gen expression, is a genetic protective factor for HCC. However, because this is the first report concerning the COX-2 -1195A>G, -765G>C, and +8473T>C polymorphisms and the risk of HCC, independent studies are needed to validate our findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21042835     DOI: 10.1007/s11010-010-0629-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  34 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

Review 2.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

3.  A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation.

Authors:  G Shaw; R Kamen
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

Review 4.  The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma.

Authors:  T Chi-Man Tang; R Tung-Ping Poon; S-T Fan
Journal:  Biomed Pharmacother       Date:  2005-10       Impact factor: 6.529

5.  Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response.

Authors:  Anastasia Papafili; Michael R Hill; David J Brull; Robin J McAnulty; Richard P Marshall; Steve E Humphries; Geoffrey J Laurent
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-10-01       Impact factor: 8.311

Review 6.  Celecoxib: a specific COX-2 inhibitor with anticancer properties.

Authors:  Alane T Koki; Jaime L Masferrer
Journal:  Cancer Control       Date:  2002 Mar-Apr       Impact factor: 3.302

Review 7.  Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

Authors:  Giampietro Gasparini; Raffaele Longo; Roberta Sarmiento; Alessandro Morabito
Journal:  Lancet Oncol       Date:  2003-10       Impact factor: 41.316

8.  Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North Indian population.

Authors:  Kshitij Srivastava; Anvesha Srivastava; Sachchida Nand Pandey; Ashok Kumar; Balraj Mittal
Journal:  J Gastroenterol       Date:  2009-05-20       Impact factor: 7.527

9.  Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators.

Authors:  D Caput; B Beutler; K Hartog; R Thayer; S Brown-Shimer; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

Review 10.  A comprehensive review of genetic association studies.

Authors:  Joel N Hirschhorn; Kirk Lohmueller; Edward Byrne; Kurt Hirschhorn
Journal:  Genet Med       Date:  2002 Mar-Apr       Impact factor: 8.822

View more
  18 in total

Review 1.  Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Shilu Mathew; Hany Abdel-Hafiz; Abbas Raza; Kaneez Fatima; Ishtiaq Qadri
Journal:  World J Hepatol       Date:  2016-04-08

2.  The significance of Exonuclease 1 K589E polymorphism on hepatocellular carcinoma susceptibility in the Turkish population: a case-control study.

Authors:  Süleyman Bayram; Hikmet Akkız; Aynur Bekar; Ersin Akgöllü; Selçuk Yıldırım
Journal:  Mol Biol Rep       Date:  2011-12-29       Impact factor: 2.316

Review 3.  Associations between Cox-2 rs20417 and rs5275 polymorphisms and the risk of hepatocellular carcinoma: a meta analysis.

Authors:  Hexing Wu; Xiangwei Wu; Guoxing Wan; Shijie Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

4.  p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case-control study.

Authors:  Ahmet Taner Sümbül; Hikmet Akkız; Süleyman Bayram; Aynur Bekar; Ersin Akgöllü; Macit Sandıkçı
Journal:  Mol Biol Rep       Date:  2011-05-24       Impact factor: 2.316

5.  COX-1 and COX-2 polymorphisms in susceptibility to cerebral palsy in very preterm infants.

Authors:  Helena Kapitanović Vidak; Tina Catela Ivković; Zoran Vidak; Sanja Kapitanović
Journal:  Mol Neurobiol       Date:  2016-01-19       Impact factor: 5.590

6.  Cyclooxygenase-2 -765 G/C polymorphisms and susceptibility to hepatitis B-related liver cancer in Han Chinese population.

Authors:  Jianhong He; Quanbao Zhang; Zhijian Ren; Yumin Li; Xun Li; Wence Zhou; Hui Zhang; Wenbo Meng; Jun Yan; Wenting He
Journal:  Mol Biol Rep       Date:  2011-07-29       Impact factor: 2.316

7.  The association between cyclooxygenase-2 1195 G/A polymorphism and hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Xianmin Bu; Chenghai Zhao
Journal:  Tumour Biol       Date:  2013-03-14

8.  Cyclooxygenase-2 -1195G>A (rs689466) polymorphism and cancer susceptibility: an updated meta-analysis involving 50,672 subjects.

Authors:  Yafeng Wang; Heping Jiang; Tianyun Liu; Weifeng Tang; Zhiqiang Ma
Journal:  Int J Clin Exp Med       Date:  2015-08-15

9.  The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.

Authors:  Khanh Vinh Quốc Lu'o'ng; Lan Thi Hoàng Nguyễn
Journal:  Cancer Manag Res       Date:  2012-12-18       Impact factor: 3.989

Review 10.  Common Variants of the Prostaglandin-Endoperoxide Synthase 2 Gene and Hepatocellular Carcinoma Susceptibility.

Authors:  Hong-Guang Li; Fang-Feng Liu; Hua-Qiang Zhu; Xu Zhou; Jun Lu; Hong Chang; Jin-Hua Hu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.